Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-011)

Next Previous
X
Search
Trial Profile

A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-011)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tildrakizumab (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms reSURFACE 2
  • Sponsors Merck Sharp & Dohme Corp.; Sun Pharma Global FZE

    • Most Recent Events

    • 06 Jul 2023 Results published in Results of Pooled analysis of 5-year safety data from reSURFACE 1 and reSURFACE 2; published in the Journal of Dermatological TreatmentJournal of Dermatological Treatment
    • 21 Mar 2023 Results of Pooled analyses from reSURFACE 1 and reSURFACE 2; analyzing efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles, presented at the American Academy of Dermatology annual Meeting 2023
    • 26 Sep 2022 Results of post-hoc analysis of two studies (reSURFACE 1 (NCT01722331) and reSURFACE 2 (NCT01729754) ) assessing tildrakizumab efficacy and safety for up to 5 years in patients with and without metabolic syndrome, published in the Journal of the European Academy of Dermatology and Venereology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top